Placental stem cell derived NK cells are effective against multiple myeloma
An investigational cell therapy is safe and leads to good response rates against multiple myeloma.
PNK-007 is a therapy derived from placental stem cells.
Placenta-derived blood stem cells are differentiated into natural killer (NK) cells.
Induce cancer cell death and recruit other immune cells into the tumour environment.
Well-tolerated and no reports of serious adverse events or dose-limiting toxicity up to now.
15 participants, from 44 to 69 years old took part in this clinical trial.
Clinical trial by Celularity presented at American Society of Haematology.